Surmodics Inc.

Surmodics Inc. is not very popular among insiders. Surmodics Inc. is a mediocre stock to choose.
Log in to see more information.
SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to t...

News

SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks Investment Research Shares of SurModics (SRDX) have been struggling lately and have lost 5.1% over the past four weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the...\n more…

Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround
Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround

Zacks Investment Research A downtrend has been apparent in SurModics (SRDX) lately with too much selling pressure. The stock has declined 5.5% over the past four weeks. However, given the fact that it is now in oversold...\n more…

SurModics Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
SurModics Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Benzinga SurModics (NASDAQ: SRDX) has been on a downward spiral lately with significant selling pressure.\n more…

SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research SurModics (SRDX) has been on a downward spiral lately with significant selling pressure. After declining 6.3% over the past four weeks, the stock looks well positioned for a trend reversal as it is...\n more…

Surmodics merger deal draws FTC second request
Surmodics merger deal draws FTC second request

Seeking Alpha - Healthcare Surmodics merger deal draws FTC second request...\n more…

SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q3 2024
SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q3 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nSRDX stock results show that Surmodics beat analyst estimates for earnings per share and beat on revenue for the third quarter of...\n more…